[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1995007987A3 - Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor - Google Patents

Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor Download PDF

Info

Publication number
WO1995007987A3
WO1995007987A3 PCT/EP1994/002990 EP9402990W WO9507987A3 WO 1995007987 A3 WO1995007987 A3 WO 1995007987A3 EP 9402990 W EP9402990 W EP 9402990W WO 9507987 A3 WO9507987 A3 WO 9507987A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigenically
protein
proteins
active proteins
disclosed
Prior art date
Application number
PCT/EP1994/002990
Other languages
French (fr)
Other versions
WO1995007987A2 (en
Inventor
Michel Bublot
Wannemaeker Catherine De
Didier Colau
Philippe Roux-Salembien
Original Assignee
Solvay
Michel Bublot
Wannemaeker Catherine De
Didier Colau
Roux Salembien Philippe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay, Michel Bublot, Wannemaeker Catherine De, Didier Colau, Roux Salembien Philippe filed Critical Solvay
Priority to JP7508961A priority Critical patent/JPH09509562A/en
Priority to KR1019960701359A priority patent/KR960705047A/en
Priority to AU76158/94A priority patent/AU7615894A/en
Priority to BR9407507A priority patent/BR9407507A/en
Priority to EP94926246A priority patent/EP0720654A1/en
Publication of WO1995007987A2 publication Critical patent/WO1995007987A2/en
Publication of WO1995007987A3 publication Critical patent/WO1995007987A3/en
Priority to NO961086A priority patent/NO961086L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Antigenically-active proteins are disclosed which are useful for formulation in vaccines for coronaviruses. The antigenically-active proteins are coronavirus proteins designated as the S protein and the SM protein. The S protein has either the A1, A2 and/or D antigenic regions modified, deleted or otherwise absent therefrom, so as to avoid provoking ADE. The signal peptide of the S protein may also be modified or deleted. Methods are disclosed for preparing the DNA coding sequences coding for these antigenically-active proteins as well as for formulating the proteins or the DNA coding sequences coding therefor in pharmaceutically acceptable carriers, including live recombinant carriers for protecting mammals against coronavirus infection. The antigenically-active proteins and vaccines disclosed herein are particularly directed to FIP and protecting felines against FIPV infection.
PCT/EP1994/002990 1993-09-16 1994-09-07 Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor WO1995007987A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP7508961A JPH09509562A (en) 1993-09-16 1994-09-07 Novel protein / polypeptide and cotransfection plasmid and recombinant live carrier thereof
KR1019960701359A KR960705047A (en) 1993-09-16 1994-09-07 New Protein / Polypeptides and Cotransfection Plasmids and Biocyclic Carriers
AU76158/94A AU7615894A (en) 1993-09-16 1994-09-07 Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor
BR9407507A BR9407507A (en) 1993-09-16 1994-09-07 Co-transfection plasmid protein for co-transfection with viral DNA live recombinant vehicle against coronavirus vaccine and processes for preparing a DNA molecule and a coronavirus and FIPV cacin to protect a mammal from coronavirus infection and a FIPV feline
EP94926246A EP0720654A1 (en) 1993-09-16 1994-09-07 Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor
NO961086A NO961086L (en) 1993-09-16 1996-03-15 New proteins / polypeptides and cotransfection plasmids and living recombinant carriers for these

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9319212.8 1993-09-16
GB9319212A GB2282601B (en) 1993-09-16 1993-09-16 Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same

Publications (2)

Publication Number Publication Date
WO1995007987A2 WO1995007987A2 (en) 1995-03-23
WO1995007987A3 true WO1995007987A3 (en) 1995-06-22

Family

ID=10742112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/002990 WO1995007987A2 (en) 1993-09-16 1994-09-07 Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor

Country Status (10)

Country Link
EP (1) EP0720654A1 (en)
JP (1) JPH09509562A (en)
KR (1) KR960705047A (en)
AU (1) AU7615894A (en)
BR (1) BR9407507A (en)
CA (1) CA2171869A1 (en)
GB (2) GB2316681B (en)
NO (1) NO961086L (en)
WO (1) WO1995007987A2 (en)
ZA (1) ZA946887B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724385B1 (en) * 1994-08-29 1996-12-13 Rhone Merieux FELINE INFECTIOUS PERITONITIS VACCINE.
FR2741806B1 (en) * 1995-11-30 1998-02-20 Rhone Merieux RECOMBINANT LIVING VACCINE BASED ON TYPE 1 FELINE HERPESVIRUS, PARTICULARLY AGAINST FELIN INFECTIOUS PERITONITIS
WO1998001570A2 (en) * 1996-07-05 1998-01-15 Vanderbilt University Mutated antibody-dependent infection enhancing domains of hiv
FR2751223B1 (en) * 1996-07-19 1998-12-04 Rhone Merieux FELIN POLYNUCLEOTIDE VACCINE FORMULA
CN1223605C (en) * 2003-05-16 2005-10-19 中国科学院微生物研究所 Polypeptide medicine for inhibiting SARS coronavirus, and derivatives and use thereof
CN113321714B (en) * 2020-02-28 2022-12-09 深圳市亚辉龙生物科技股份有限公司 Recombinant N protein of SARS-CoV-2 and its preparation and purification method
US20230331782A1 (en) * 2020-09-08 2023-10-19 The Trustees Of The University Of Pennsylvania Compositions and Methods for Reducing Risk of Vaccine-Enhanced Disease

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181117A2 (en) * 1984-11-01 1986-05-14 American Home Products Corporation Oral vaccines
EP0264979A1 (en) * 1986-09-05 1988-04-27 Duphar International Research B.V New antigenically active proteins and peptides, and feline infectious peritonitis virus (FIPV) vaccines
EP0376744A1 (en) * 1988-12-30 1990-07-04 Scios Nova Inc. Feline infectious peritonitis virus diagnostic tools
EP0411684A2 (en) * 1989-07-12 1991-02-06 Duphar International Research B.V New antigenically active proteins/peptides, and feline infectious virus (FIPV)-vaccines
WO1992008487A1 (en) * 1990-11-14 1992-05-29 Smithkline Beecham Corporation Recombinant feline coronavirus s proteins
WO1993015762A1 (en) * 1992-02-18 1993-08-19 Parhelion Corporation Feline infectious peritonitis vaccine and method of preparation
WO1993023423A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Canine coronavirus s gene and uses therefor
WO1993023422A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Compositions and methods for vaccination against coronaviruses

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181117A2 (en) * 1984-11-01 1986-05-14 American Home Products Corporation Oral vaccines
EP0264979A1 (en) * 1986-09-05 1988-04-27 Duphar International Research B.V New antigenically active proteins and peptides, and feline infectious peritonitis virus (FIPV) vaccines
EP0376744A1 (en) * 1988-12-30 1990-07-04 Scios Nova Inc. Feline infectious peritonitis virus diagnostic tools
EP0411684A2 (en) * 1989-07-12 1991-02-06 Duphar International Research B.V New antigenically active proteins/peptides, and feline infectious virus (FIPV)-vaccines
WO1992008487A1 (en) * 1990-11-14 1992-05-29 Smithkline Beecham Corporation Recombinant feline coronavirus s proteins
WO1993015762A1 (en) * 1992-02-18 1993-08-19 Parhelion Corporation Feline infectious peritonitis vaccine and method of preparation
WO1993023423A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Canine coronavirus s gene and uses therefor
WO1993023422A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Compositions and methods for vaccination against coronaviruses

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAVANAGH D. & BROWN T.D. (EDS.): "ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY: Coronaviruses and their diseases", 1990 *
CORAPI W.V. ET AL.: "Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus", JOURNAL OF VIROLOGY, vol. 66, November 1992 (1992-11-01), pages 6695 - 6705 *
HORSBURGH B.C. ET AL.: "Analysis of a 9.6 kb sequence from the 3' end of canine coronavirus genomic RNA", JOURNAL OF GENERAL VIOROLOGY, vol. 73, 1992, pages 2849 - 2862 *
JOHNSON P. A. ET AL.: "Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1", JOURNAL OF VIROLOGY, vol. 66, no. 5, 1992, pages 2952 - 2965 *
OLSEN C. W. ET AL.: "Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages", JOURNAL OF VIROLOGY, vol. 66, February 1992 (1992-02-01), pages 956 - 965 *
WESSELING J. G. ET AL.: "Nucleotide sequence and expression of the spike (S) gene of canine coronavirus and comparison with the S protein of feline and porcine coronaviruses", JOURNAL OF GENERAL VIROLOGY, vol. 75, 1994, pages 1789 - 1794 *

Also Published As

Publication number Publication date
AU7615894A (en) 1995-04-03
WO1995007987A2 (en) 1995-03-23
NO961086L (en) 1996-05-09
GB9319212D0 (en) 1993-11-03
GB2282601B (en) 1998-04-15
GB9722558D0 (en) 1997-12-24
KR960705047A (en) 1996-10-09
CA2171869A1 (en) 1995-03-23
BR9407507A (en) 1997-01-07
GB2316681A (en) 1998-03-04
GB2316681B (en) 1998-04-15
JPH09509562A (en) 1997-09-30
GB2282601A (en) 1995-04-12
NO961086D0 (en) 1996-03-15
ZA946887B (en) 1995-06-27
EP0720654A1 (en) 1996-07-10

Similar Documents

Publication Publication Date Title
HUP9901186A2 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
EP0835315A4 (en) Vaccine for porcine reproductive and respiratory syndrome virus
FR2741806B1 (en) RECOMBINANT LIVING VACCINE BASED ON TYPE 1 FELINE HERPESVIRUS, PARTICULARLY AGAINST FELIN INFECTIOUS PERITONITIS
HK1053662A1 (en) Gag antigen and its use for the detection of lav infection and in immunogenic compositions
AU1353295A (en) Peptides derived from a retrovirus of the HIV group, and their use
WO1992017493A3 (en) Peptides and mixtures thereof for detecting antibodies to hepatitis c virus (hcv)
MXPA01008966A (en) Nucleic acid respiratory syncytial virus vaccines.
CA2186044A1 (en) Novel mutated viruses, anti-viral compounds and novel methods of making vaccines
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
WO2003065973A3 (en) Multivalent streptococcal vaccine compositions and methods for use
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
WO1995007987A3 (en) Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor
EP0652287A3 (en) Poxviral vectors and their use as a vaccine against feline infectious peritonitis virus disease.
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
ATE346931T1 (en) CLOSTRIDIUM PERFRINGENS VACCINE
WO2003013599A3 (en) Anti-coronavirus vaccine
AU5776799A (en) Modified hcv peptide vaccines
AUPQ347199A0 (en) Novel polypeptide fragments
EP0256677A3 (en) Pseudorabies virus recombinants and their use in the production of proteins
EP0411684A3 (en) New antigenically active proteins/peptides, and feline infectious virus (fipv)-vaccines
WO1993014206A3 (en) Synthetic peptides for a rubella vaccine
EP1174439A3 (en) Compositions and methods for treating infections using analogues of indolicidin
CA2198743A1 (en) Feline infectious peritonitis vaccine
HK1045810A1 (en) Allergy vaccines and their preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA JP KR NO NZ US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA JP KR NO NZ US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 1994926246

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 273014

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2171869

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1996 617822

Country of ref document: US

Date of ref document: 19960524

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1994926246

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994926246

Country of ref document: EP